Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients

Journal of International Medical Research

Volumn 28, Issue 4, 2000, Pages 149-167

  Stangier, J ^a   Su, C A P F ^a   Roth, W ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

AT1 receptor antagonist; Hypertension; Pharmacokinetics; Telmisartan; Tolerability

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ENALAPRIL; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN; OROSOMUCOID; PLACEBO; SERUM ALBUMIN; TELMISARTAN; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PLASMA PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TIME;

EID: 0033840660     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000002800401     Document Type: Article

References (33)

1. The renin system and new understanding of the complications of hypertension and their treatment
2. Molecular basis of human hypertension: Role of angiotensinogen
3. Control of sodium excretion by angiotensin II: Intrarenal mechanisms and blood pressure regulation
4. Angiotensin II receptor subtypes: Selective antagonists and functional correlates
5. Angiotensin II - Possible adverse effects on arteries, heart, brain, and kidney: Experimental, clinical, and epidemiological evidence
6. Angiotensin-converting enzyme inhibitors in the treatment of hypertension
7. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases
8. Bradykinin-induced broncho-constriction in humans. Mode of action
9. The effect of sulindac on the abnormal cough reflex associated with dry cough
10. Change in cough reflex after treatment with enalapril and ramipril
11. The positive association of cough with angiotensin-converting enzyme inhibitors
12. Angiotensin-II receptors: New targets for anti-hypertensive therapy
13. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
14. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
15. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
16. Telmisartan blood pressure monitoring group: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
17. Placebo-controlled, multicenter comparison of 36-hour blood pressure control in ambulatory hypertensives with telmisartan and losartan
18. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension
19. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
20. Once-daily telmisartan compared with enalapril in the treatment of hypertension
21. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension
22. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertensiom
23. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists
24. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships
25. Chemistry of telmisartan, a highly lipophilic angiotensin II antagonist with a long duration of action
26. 14C]telmisartan in healthy volunteers
27. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
28. Age-related changes in hepatic function. Implications for drug therapy
29. The aging liver: Drug clearance and an oxygen diffusion barrier hypothesis
30. Drugs and the liver. Part III: Aging of the liver and the metabolism of drugs
31. The effects of age and gender on the pharmacokinetics of irbesartan
32. Gender effects in pharmacokinetics and pharmacodynamics
33. Assessing the safety profile of a new antihypertensive agent